We are live on ! Find out more
OAM

Oxford Asset Management Portfolio holdings

AUM $232M
1-Year Est. Return 31%
This Fund
S&P 500
This Quarter Est. Return
-10.3%
1 Year Est. Return
+31%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$3.85B
AUM Growth
-$949M
Cap. Flow
-$393M
Cap. Flow %
-10.22%
Top 10 Hldgs %
10.07%
Holding
2,323
New
652
Increased
471
Reduced
539
Closed
577

Sector Composition

Rank Sector Weight
1 Technology 15.44%
2 Consumer Discretionary 14.53%
3 Healthcare 13.43%
4 Industrials 13.16%
5 Financials 12.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NTLA icon
1601
Intellia Therapeutics
NTLA
$1.67B
$144K ﹤0.01%
+10,586
New +$197K
CFRX
1602
DELISTED
ContraFect Corporation
CFRX
$144K ﹤0.01%
+118
New +$187K
AEG icon
1603
Aegon
AEG
$14.1B
$143K ﹤0.01%
+35,958
New +$175K
LTN.WS
1604
DELISTED
Union Acquisition Corp.
LTN.WS
$143K ﹤0.01%
570,000
LJPC
1605
DELISTED
La Jolla Pharmaceutical Company
LJPC
$143K ﹤0.01%
+15,173
New +$228K
JNCE
1606
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$142K ﹤0.01%
+42,231
New +$197K
MLNT
1607
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
$141K ﹤0.01%
+35,643
New +$456K
GIG.WS
1608
DELISTED
GigCapital, Inc. Warrants, each whole Warrant exercisable for one share of Common Stock at an exerci
GIG.WS
$141K ﹤0.01%
581,250
RMNI icon
1609
Rimini Street
RMNI
$471M
$140K ﹤0.01%
199,800
RDHL
1610
Redhill Biopharma
RDHL
$3.68M
$138K ﹤0.01%
+25
New +$192K
OBSV
1611
DELISTED
ObsEva SA Ordinary Shares
OBSV
$137K ﹤0.01%
+10,843
New +$161K
SECO
1612
DELISTED
Secoo Holding Limited ADR
SECO
$137K ﹤0.01%
+1,511
New +$151K
FCSC
1613
DELISTED
Fibrocell Science Inc.
FCSC
$137K ﹤0.01%
91,533
+79,862
+684% +$160K
PTN
1614
Palatin Technologies
PTN
$13.8M
$133K ﹤0.01%
150
-71
-32% -$73.9K
MFIN icon
1615
Medallion Financial
MFIN
$250M
$132K ﹤0.01%
+28,043
New +$172K
DWSN icon
1616
Dawson Geophysical
DWSN
$135M
$130K ﹤0.01%
38,357
+22,711
+145% +$108K
VVUS
1617
DELISTED
Vivus Inc
VVUS
$130K ﹤0.01%
58,488
+39,132
+202% +$135K
APVO icon
1618
Aptevo Therapeutics
APVO
$5.21M
0
DNTH icon
1619
Dianthus Therapeutics
DNTH
$6.09B
$128K ﹤0.01%
+1,403
New +$191K
GENC icon
1620
Gencor Industries
GENC
$212M
$128K ﹤0.01%
11,645
-15,968
-58% -$182K
WSR
1621
DELISTED
Whitestone REIT
WSR
$125K ﹤0.01%
+10,179
New +$138K
INWK
1622
DELISTED
InnerWorkings, Inc.
INWK
$125K ﹤0.01%
+33,452
New +$186K
MGTX icon
1623
MeiraGTx Holdings
MGTX
$1.21B
$124K ﹤0.01%
12,876
-8,399
-39% -$106K
NAAS
1624
NaaS Technology Inc
NAAS
$59.1M
$123K ﹤0.01%
+2
New +$157K
MGI
1625
DELISTED
MoneyGram International, Inc. New
MGI
$122K ﹤0.01%
61,012
+19,677
+48% +$63.3K

Similar funds

Oxford Asset Management's Q4 2018 Portfolio in Review

As of Q4 2018, Oxford Asset Management held 2,323 positions worth $3.85B, down 20% from $4.8B the previous quarter. Its ten largest holdings account for 10% of the portfolio.

Oxford Asset Management withdrew a net $393M in Q4 2018, closing 577 positions and reducing 539 holdings. Its most notable exit was Envision Healthcare Holdings Inc, an estimated $105M position sold in full.

By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 17% a quarter earlier, followed by Consumer Discretionary and Healthcare.

Against the trend, Oxford Asset Management opened a new position in Athenahealth, Inc. worth $69.9M.

  • Oxford Asset Management's largest Q4 2018 buy was Athenahealth, Inc.: 530,000 shares worth $69.9M.
  • Oxford Asset Management added most to Integrated Device Technology I in Q4 2018, an estimated $34.6M increase.
  • Oxford Asset Management's biggest Q4 2018 reduction was GE Aerospace, cutting an estimated $18.1M.
  • Oxford Asset Management fully exited Envision Healthcare Holdings Inc in Q4 2018, selling an estimated $105M.
  • Oxford Asset Management's ten largest holdings make up 10% of its $3.85B portfolio in Q4 2018.
  • Oxford Asset Management opened 652 new positions and closed 577 in Q4 2018.
  • Oxford Asset Management's portfolio value fell 20% quarter-over-quarter to $3.85B.

Based on Oxford Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.